Scarica l'app Stockscreener
4.00
4.08%
0.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.83
Aprire:
$3.84
Volume 24 ore:
8.08M
Relative Volume:
1.18
Capitalizzazione di mercato:
$945.91M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.8868
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+4.63%
1M Prestazione:
+28.59%
6M Prestazione:
+229.45%
1 anno Prestazione:
+48.19%
Intervallo 1D:
$3.80
$4.125
Intervallo di 1 settimana:
$3.675
$4.125
Portata 52W:
$0.6925
$4.125
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.99 | 907.98M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
117.45 | 52.03B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.42 | 45.40B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.575 | 42.13B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.04 | 34.19B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
487.70 | 20.88B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Iniziato | Piper Sandler | Overweight |
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Yahoo Finance
Esperion announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees - Quiver Quantitative
Esperion (NASDAQ: ESPR) awards 380K options, 435,536 RSUs in inducement grants - Stock Titan
Is Esperion Therapeutics Inc a good long term investmentMarket Sentiment Indicators & High Profit Market Tips - earlytimes.in
Esperion Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Will Esperion Therapeutics Inc. (0ET) stock enhance shareholder valueEarnings Overview Summary & Smart Money Movement Alerts - Newser
Esperion stock hits fair value target with 77% gain since April 2024 - Investing.com Australia
Esperion Therapeutics, Inc.Common Stock (Nasdaq:ESPR) Stock Quote - Markets Financial Content
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Esperion Therapeutics Inc. (0ET) stock a top dividend aristocrat candidateTrend Reversal & Stepwise Trade Execution Plans - Newser
Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week HighShould You Buy? - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Trading 6% HigherHere's What Happened - MarketBeat
Esperion a new overweight at Piper Sandler on CV franchise - MSN
Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler - MarketBeat
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Esperion Therapeutics: Soaring Momentum Observed - StocksToTrade
Piper Sandler Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - Nasdaq
Piper Sandler initiates Esperion Therapeutics stock with Overweight rating By Investing.com - Investing.com South Africa
Esperion’s Strategic Moves: What It Means? - StocksToTrade
Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage - marketscreener.com
Esperion Stock Grows Amid Promising Japanese Partnership and Q3 Earnings - timothysykes.com
Why Analysts Are Rewriting Esperion’s Story After New Pipeline Results and Global Partnerships - Yahoo Finance
Esperion gains after Piper Sandler initiates with 'overweight' rating - TradingView
United StatesGoodwin Advises Esperion On $75 Million Underwritten Public Offering - Mondaq
Piper Sandler initiates Esperion Therapeutics stock with Overweight rating - Investing.com
Esperion shares rise as Otsuka launches NEXLETOL in Japan By Investing.com - Investing.com Nigeria
Esperion Therapeutics Partner Rolls Out Nexletol Tablets in Japan to Treat Hypercholesterolemia - MarketScreener
Esperion stock rises after $90 million payment from Japan launch By Investing.com - Investing.com Australia
Esperion stock rises after $90 million payment from Japan launch - Investing.com
Is Esperion Therapeutics Inc. stock undervalued vs historical averages2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Esperion shares rise as Otsuka launches NEXLETOL in Japan - Investing.com India
Esperion partner Otsuka launches Nexletol in Japan - MarketScreener
Esperion Partners with Otsuka to Launch NEXLETOL in Japan, Secures $90 Million Payment - Quiver Quantitative
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia - The Manila Times
Esperion (NASDAQ: ESPR) earns $90M with Otsuka's NEXLETOL launch in Japan market - Stock Titan
Is Esperion Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Will Esperion Therapeutics Inc. stock recover faster than marketTreasury Yields & Daily Profit Focused Screening - newser.com
Why retail investors favor Esperion Therapeutics Inc. stock2025 Big Picture & High Conviction Buy Zone Picks - newser.com
Esperion: HLS Therapeutics (TSX:HLS) Secures Health Canada Clearance for NILEMDO® - Kalkine Media
Why Esperion Therapeutics Inc. is moving todayMarket Movement Recap & Expert Verified Movement Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.Portfolio Return Summary & Low Drawdown Momentum Ideas - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersQuarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Can Esperion Therapeutics Inc. stock double in next 5 yearsJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):